---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016015"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:05:16.738028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds

## Summary
- Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.
- Cash, cash equivalents, and short-term investments ~$127M as of June 30, 2022.
- R&D expenses $8.1M (up $1.8M YoY); G&A $4.3M (up $1.4M).
- Positive results from REN001 Phase 1b LC-FAOD study; plan to meet regulators.
- STRIDE pivotal PMM study enrollment two-thirds complete; on track for year-end 2022.

## SEC filing metadata
- accession: 0000950170-22-016015
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/0000950170-22-016015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017022016015/rphm-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016015
- JSON: https://secwatch.observer/filing/0000950170-22-016015.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.